Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06591793
PHASE1/PHASE2

Study of Subretinally Injected AAVB-081 in Patients With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa

Sponsor: AAVantgarde Bio Srl

View on ClinicalTrials.gov

Summary

The purpose of the 081-101 study is to evaluate the safety and tolerability of a single subretinal injection of AAVB-081 in USH1B patients with retinitis pigmentosa due to a mutation in the MYO7A gene. The study will also assess the initial efficacy following AAVB-081 administration.

Official title: A Phase 1/2 Multicenter, Open-label, Dose Escalation, Safety and Efficacy Study of Subretinal Administration of Dual AAV8.MYO7A, AAVB-081 in Subjects With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa

Key Details

Gender

All

Age Range

18 Years - 50 Years

Study Type

INTERVENTIONAL

Enrollment

15

Start Date

2024-07-02

Completion Date

2029-07

Last Updated

2025-05-02

Healthy Volunteers

No

Interventions

BIOLOGICAL

AAVB-081

Single subretinal administration

Locations (3)

University of Campania Luigi Vanvitelli

Naples, Italy

Moorfields Eye Hospital

London, United Kingdom

Retina Clinic London

London, United Kingdom